Titlebook: Resistance to Targeted Therapies Against Adult Brain Cancers; Amanda Tivnan Book 2016 Springer International Publishing AG 2016 Brain canc

Juvenile

hemorrhage

露天歷史劇

Congeal

信條

The Blood-Brain Barrier in Glioblastoma: Pathology and Therapeutic Implications, associated with rapid and aggressive tumour growth with associated cerebral oedema. Central to the difficulty associated with treating GBM is the challenge of getting chemotherapeutic drugs to cross the blood-brain barrier (BBB). Although vasculature within and around a GBM becomes more permeable d

同步信息

Resistance of Brain Tumours to Small-Molecule-Targeted Therapies: Lessons from Various Cancer Types resection or sequential or concurrent chemoradiotherapy with chemotherapy such as temozolomide. Despite improvements in these treatments, survival rate is less than 10 % 5 years after diagnosis, and there are limited second-line treatments available. Although recent improvements in understanding th

卡死偷電

PURG

ATP861

Imaging Targeted Therapy Response and Resistance in Glioblastoma, GBM, the disease still remains in desperate need of effective treatment options resulting in long-term improvements in overall patient survival. Molecularly targeted therapies, anti-angiogenic therapy and immunotherapy are promising avenues under investigation as future therapeutic options. Molecul

Maximizer

Drug Resistance in Malignant Meningiomas,e benign, approximately 5–15 % of meningiomas are non-benign. These tumors are histologically Grade II and III and have a propensity to be aggressive and occasionally metastasize. Multiple genetic abnormalities and epigenetic changes are involved in the formation and malignant transformation of meni